Milbank LLP advised Carl Zeiss Vision International GmbH on its acquisition of 100% of the shares in Brighten Optix, a leading player in the field of orthokeratology and specialty contact lenses listed on the Taipei Exchange. The acquisition is expected to close in early 2026 and remains subject to completion of certain conditions and all applicable regulatory approvals.
Brighten Optix's products are widely used by eye care professionals across Greater China and Southeast Asia to help manage myopia in children.
This acquisition will enhance ZEISS Vision Care's portfolio of myopia management solutions and further reinforce its leading global position in vision care by also integrating specialty contact lenses.
"We are pleased to have advised ZEISS Vision Care on this strategic acquisition," said Neeraj Budhwani, Milbank Global Corporate partner. "This transaction strengthens ZEISS's position in the growing myopia management market and demonstrates its commitment to innovation in vision care solutions."
The Hong Kong-based Milbank deal team was led by Mr. Budhwani and associate Matthew Leung.
